Viral kinetic modeling: State of the art

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 5, 2014, Pages 431-443

  Canini, Laetitia ^a   Perelson, Alan S ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Antiviral drug; Hepatitis C; Influenza; Mathematical modeling; Resistance emergence; Viral kinetics

Indexed keywords

OSELTAMIVIR; PROTEINASE INHIBITOR; ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CELL SPREADING; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; INFECTION RATE; INFLUENZA; INNATE IMMUNITY; KINETICS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; REVIEW; STEADY STATE; VIRAL KINETIC; VIRION; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; BIOLOGICAL MODEL; COMPUTER SIMULATION; IMMUNOLOGY; INFLUENZA, HUMAN; VIROLOGY;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; DISEASE PROGRESSION; HEPATITIS C; HUMANS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL;

EID: 84910109211     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9363-3     Document Type: Review

References (101)

1. Ho DD et al (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373(6510):123–126
2. Perelson AS (2002) Modelling viral and immune system dynamics. Nat Rev Immunol 2(1):28–36
3. Perelson AS et al (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188–191
4. Perelson AS et al (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271(5255):1582–1586
5. Wei X et al (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373(6510):117–122
6. Neumann AU et al (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282(5386):103–107
7. Ciupe SM et al (2007) The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci USA 104(12):5050–5055
8. Ciupe SM et al (2007) Modeling the mechanisms of acute hepatitis B virus infection. J Theor Biol 247(1):23–35
9. Dahari H et al (2009) Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology 49(1):32–38
10. Lewin SR et al (2001) Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 34(5):1012–1020
11. Murray JM et al (2005) Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci USA 102(49):17780–17785
12. Nowak MA et al (1996) Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 93(9):4398–4402
13. Ribeiro RM et al (2010) Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J Infect Dis 202(9):1309–1318
14. Ribeiro RM, Lo A, Perelson AS (2002) Dynamics of hepatitis B virus infection. Microb Infect 4(8):829–835
15. Emery VC, Griffiths PD (2000) Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 97(14):8039–8044
16. Emery VC et al (2012) Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy. J Clin Virol 54(1):56–60
17. Regoes RR et al (2006) Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis. Proc R Soc B 273(1596):1961–1967
18. Schiffer JT, Corey L (2013) Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med 19(3):280–288
19. Schiffer JT et al (2013) Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. Elife 2:e00288
20. Schiffer JT et al (2011) The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral–host interactions. J Infect Dis 204(4):554–561
21. Baccam P et al (2006) Kinetics of influenza A virus infection in humans. J Virol 80(15):7590–7599
22. Beauchemin C, Samuel J, Tuszynski J (2005) A simple cellular automaton model for influenza A viral infections. J Theor Biol 232(2):223–234
23. Bocharov GA, Romanyukha AA (1994) Mathematical model of antiviral immune response. III. Influenza A virus infection. J Theor Biol 167(4):323–360
24. Canini L, Carrat F (2011) Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J Virol 85(6):2764–2770
25. Hancioglu B, Swigon D, Clermont G (2007) A dynamical model of human immune response to influenza A virus infection. J Theor Biol 246(1):70–86
26. Handel A, Longini IM Jr, Antia R (2010) Towards a quantitative understanding of the within-host dynamics of influenza A infections. J R Soc Interface 7(42):35–47
27. Miao H et al (2010) Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol 84(13):6687–6698
28. Pawelek KA et al (2012) Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput Biol 8(6):e1002588
29. Saenz RA et al (2010) Dynamics of influenza virus infection and pathology. J Virol 84(8):3974–3983
30. Smith AM et al (2011) Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics. PLoS Comput Biol 7(2):e1001081
31. Smith AM, Perelson AS (2011) Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip Rev Syst Biol Med 3(4):429–445
32. Perelson AS, Rong L, Hayden FG (2012) Combination antiviral therapy for influenza: predictions from modeling of human infections. J Infect Dis 205(11):1642–1645
33. Murillo LN, Murillo MS, Perelson AS (2013) Towards multiscale modeling of influenza infection. J Theor Biol 332:267–290
34. Smith AM et al (2013) Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog 9(3):e1003238
35. Asquith B, Bangham CR (2007) Quantifying HTLV-I dynamics. Immunol Cell Biol 85(4):280–286
36. Heffernan J, Keeling MJ (2008) An in-host model of acute infection: measles as a case study. Theor Popul Biol 73(1):134–147
37. Zhang J et al (2013) Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection. J Virol 87(7):4052–4059
38. Snoeck E et al (2010) A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 87(6):706–713
39. Guedj J et al (2014) Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in HCV genotype 2/3 patients. Hepatology 59(5):1706–1714
40. Gao M et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465(7294):96–100
41. Beauchemin CA et al (2008) Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol 254(2):439–451
42. Bochud P-Y et al (2011) IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 55(5):980–988
43. Dahari H et al (2011) Hepatitis C viral kinetics in the era of direct acting antiviral agents and interleukin-28B. Curr Hepat Rep 10(3):214–227
44. Guedj H et al (2012) The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with PEG-IFN-alfa-2a and ribavirin. J Viral Hepat 19(7):488–496
45. Guedj J et al (2012) Understanding silibinin’s modes of action against HCV using viral kinetic modeling. J Hepatol 56(5):1019–1024
46. Lagging M et al (2011) Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 6(2):e17232
47. Layden-Almer JE et al (2003) Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37(6):1343–1350
48. Neumann AU et al (2000) Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182(1):28–35
49. Herrmann E et al (2003) Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37(6):1351–1358
50. Dahari H, Ribeiro RM, Perelson AS (2007) Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 46(1):16–21
51. Dahari H et al (2007) Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 247(2):371–381
52. Rong L et al (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2(30):30ra32
53. Dahari H et al (2010) Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol 53(3):460–467
54. Guedj J et al (2010) A perspective on modelling hepatitis C virus infection. J Viral Hepat 17(12):825–833
55. Shudo E, Ribeiro RM, Perelson AS (2009) Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol 5(3):321–332
56. Talal AH et al (2006) Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43(5):943–953
57. Adiwijaya BS et al (2012) A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol 8(1):e1002339
58. Powers KA et al (2003) Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 23:13–18
59. Holford NH, Sheiner LB (1981) Understanding the dose–effect relationship. Clin Pharmacokinet 6(6):429–453
60. Guedj J et al (2012) Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 55(4):1030–1037
61. Shudo E et al (2008) A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther 13(7):919–926
62. Shudo E, Ribeiro R, Perelson A (2008) Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α-2b. J Viral Hepat 15(5):379–382
63. Conway JM, Perelson AS (2014). Hepatitis C virus infection model with time-varying drug effectivenss: solution and analysis (submitted)
64. Guedj J et al (2014) Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther 19(2):211–220
65. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47(2):331–385
66. Ribeiro RM et al (2012) Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 8(8):e1002881
67. Drake JW et al (1998) Rates of spontaneous mutation. Genetics 148(4):1667–1686
68. Kieffer T et al (2007) Evaluation of viral variants during a Phase 2 study (PROVE2) of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1-infected patients. Hepatology 46(Suppl 1):862
69. Rong L, Ribeiro RM, Perelson AS (2012) Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol 74(8):1789–1817
70. Adiwijaya BS et al (2010) A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol 6(4):e1000745
71. Guedj J et al (2013) Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA 110(10):3991–3996
72. Rong L, Perelson AS (2013) Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. Math Biosci 245(1):22–30
73. Rong L et al (2013) Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol 9(3):e1002959
74. Kandathil AJ et al (2013) Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology 145(6):1404.e10–1413.e10
75. Graw F et al (2014) Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes (submitted)
76. Graw F, Perelson AS (2013) Spatial aspects of HIV infection. In: Mathematical methods and models in biomedicine. Springer, Berlin, pp 3–31
77. Bauer AL, Beauchemin CA, Perelson AS (2009) Agent-based modeling of host–pathogen systems: the successes and challenges. Inf Sci 179(10):1379–1389
78. Chao DL et al (2010) FluTE, a publicly available stochastic influenza epidemic simulation model. PLoS Comput Biol 6(1):e1000656
79. Ferguson NM et al (2005) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437(7056):209–214
80. Mills CE, Robins JM, Lipsitch M (2004) Transmissibility of 1918 pandemic influenza. Nature 432(7019):904–906
81. Jansen CA et al (2013) Differential lung NK cell responses in avian influenza virus infected chickens correlate with pathogenicity. Sci Rep 3:2478
82. Pommerenke C et al (2012) Global transcriptome analysis in influenza-infected mouse lungs reveals the kinetics of innate and adaptive host immune responses. PLoS ONE 7(7):e41169
83. +-T-cell-deficient mice. J Virol 76(23):12388–12393
84. Tridane A, Kuang Y (2010) Modeling the interaction of cytotoxic T lymphocytes and influenza virus infected epithelial cells. Math Biosci Eng 7(1):171–185
85. Ginaldi L et al (2001) Immunosenescence and infectious diseases. Microbes Infect 3(10):851–857
86. Hernandez-Vargas EA et al (2014) The effects of aging on influenza virus infection dynamics. J Virol 88(8):4123–4131
87. Hayden FG et al (1998) Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Investig 101(3):643
88. Anderson RM, May RM (1982) Directly transmitted infectious diseases: control by vaccination. Science 215(4536):1053–1060
89. Handel A, Longini IM Jr, Antia R (2007) Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput Biol 3(12):e240
90. Canini L et al (2014) Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study. PLoS Comput Biol 10(4):e1003568
91. Heldt FS et al (2013) Multiscale modeling of influenza A virus infection supports the development of direct-acting antivirals. PLoS Comput Biol 9(11):e1003372
92. Guedj J, Perelson AS (2011) Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 53(6):1801–1808
93. Adiwijaya BS et al (2011) Modeling clinical and virology data from phase 2 and 3 studies support 12-week telaprevir duration in combination with 24- or 48-week peginterferon/ribavirin. Gastroenterology 140(5):943
94. Kohli A et al (2014) Hepatitis C antiviral therapy for 6 or 12 weeks: final results of the SYNERGY trial. In: Conference on retroviruses and opportunistic infections, 2014
95. Wieland S et al (2014) Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59(6):2121–2130
96. Sidharthan S et al (2014) Predicting response to all-oral directly acting antiviral therapy for hepatitis C using results of Roche and Abbott HCV viral load assays. Hepatol Int 8(S1):S227–S228
97. Cowling BJ et al (2010) Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 362(23):2175–2184
98. Atkinson A, Donev A (1992) Optimum experimental designs. Clarendon, Oxford
99. Canini L, Carrat F (2011) Viral kinetics studies on influenza: when and how many times are nasal samples to be collected? Influenza Other Respir Viruses 5(S1):144–147
100. Gustin KM et al (2011) Influenza virus aerosol exposure and analytical system for ferrets. Proc Natl Acad Sci USA 108(20):8432–8437
101. Eccles R (2005) Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 5(11):718–725